High specificity to a primary target receptor is not only important when developing novel therapeutics, it may also be critical in the development of reliable diagnostic tools. Uniquely, for diagnostics that are intended to be physically administered to patients in order to detect and quantify disease in situ, polyspecificity also raises the risk of adverse reactions in addition to potentially hampering diagnostic effectiveness.
NanoMab is an innovative developer of diagnostics and precision cancer therapies. The company is currently running human trials of novel in vivo diagnostics for specific tumours. Radioactive isotopes that are conjugated to tumour targeting moieties are injected into the patient. Whole-body imaging scans then provide information on both primary and metastatic tumours and can also be used to select patient and monitor responses to cancer treatment. Here we discuss a NanoMab lung cancer diagnostic which is now commencing Phase 2 studies1. Demonstrating specificity to the primary target – PD-L1 – was one of the key steps in the preparation of the regulatory package that was required prior to advancement into the clinic.